Johnson & Johnson Innovation Catalyzes New and Exciting Science and Technology in Pharmaceutical, Medical Device, Diagnostic and Consumer Healthcare Spaces
Deals span new approaches for cancer, diabetes, autoimmune disease and Alzheimer's, exciting technologies such as 3-D printing for trauma use, sedation monitoring, cardiac remodeling, probiotics for skin infections
NEW BRUNSWICK (June 19, 2014) – Johnson & Johnson Innovation, LLC today announced 12 new alliances with life science companies and research institutions around the globe to explore early-stage innovation in a broad range of therapeutic areas and across pharmaceuticals, medical device and diagnostics and consumer healthcare.
"The future of healthcare will be defined by companies, academic institutions and governments that collaborate to leverage existing strengths, while at the same time think outside current paradigms and experiment with new ways of innovating," said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson and Worldwide Chairman, Pharmaceuticals. "By being where these new frontiers in science and technology are being forged, our goal is to translate these insights into promising treatments for the future."
Launched more than a year ago, the Johnson & Johnson Innovation centers are working globally with life science researchers and entrepreneurs to identify exciting early-stage technologies and translate them into solutions for patients.
Read the full article: http://tissuesys.com/trs_media/publications/Johnson&Johnson-Innovation.pdf